VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LEGNLegend Biotech Corporation
$16.25$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. LEGN
  4. Financial Ratios

Legend Biotech Corporation (LEGN) Financial Ratios

Latest Ratios: P/E Ratio -9999.0x · EV/EBITDA 29.8x · ROE -29.1%. (2017–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

LEGN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$3.0B$4.0B$5.9B$10.6B$7.9B$6.6B$3.3B———
Enterprise Value$2.5B$3.5B$6.0B$9.6B$7.4B$6.0B$2.9B———
P/E Ratio →-9999.00—————————
P/S Ratio2.213.899.4937.1667.8695.3944.36———
P/B Ratio2.994.005.728.4710.678.575.57———
P/FCF——————————
P/OCF——————————

P/E links to full P/E history page with 30-year chart

LEGN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—3.429.5933.8363.5787.1638.33———
EV / EBITDA29.84—————————
EV / EBIT——————————
EV / FCF——————————

LEGN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin60.3%60.3%62.6%49.4%44.1%100.0%100.0%100.0%100.0%100.4%
Operating Margin-13.3%-13.3%-48.3%-154.1%-389.4%-570.0%—-214.4%-3.1%58.4%
Net Profit Margin-28.8%-28.8%-28.2%-181.8%-381.5%-586.4%-355.2%-164.4%-5.7%39.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE-29.1%-29.1%-15.4%-51.9%-59.1%-59.2%-112.2%—-26.7%77.0%
ROA-17.4%-17.4%-10.1%-32.6%-36.4%-43.8%-52.8%-28.3%-0.8%3.9%
ROIC-12.7%-12.7%-32.3%-120.9%-154.3%-170.4%———100.2%
ROCE-11.0%-11.0%-20.1%-33.0%-47.4%-52.4%—-61.7%-0.7%7.4%

LEGN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity0.410.410.340.260.380.160.01—0.500.02
Debt / EBITDA————————28.970.02
Net Debt / Equity—-0.490.06-0.76-0.67-0.74-0.76—-23.80-0.15
Net Debt / EBITDA————————-1381.54-0.13
Debt / FCF————————-0.72—
Interest Coverage-12.21-12.21-6.32-22.87-40.29-451.44-73.20-594.23-18.71—

Net cash position: cash ($902M) exceeds total debt ($414M)

LEGN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio1.961.964.626.923.694.145.141.622.054.43
Quick Ratio1.911.914.546.833.664.145.121.612.054.43
Cash Ratio1.491.494.046.053.443.854.381.251.360.04
Asset Turnover—0.590.380.150.090.060.100.210.110.10
Inventory Turnover12.7512.759.817.426.31————-8.73
Days Sales Outstanding—88.7972.67201.05138.87310.49402.06211.19806.533538.66

LEGN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield——————————
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield——————————
FCF Yield——————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%———
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%———
Shares Outstanding—$184M$183M$176M$159M$141M$118M$132M$100M$132M

Key Metrics

Growth RegimeExpanding
ProfitabilityWeak
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Operating cash conversion lagging earnings

Premium Multiples Price in Carvykti Scale

Based on reported figures, LEGN trades at 2.38 times sales and 32.58 times trailing EV/EBITDA, a premium that implies the market expects Carvykti revenue to compound well beyond current levels before the equity justifies the price.

The reported trailing P/E of -9999 is not meaningful because earnings are distorted by sporadic net income swings, so EV/EBITDA and P/S are the more usable anchors. A 32.58 times EV/EBITDA multiple, compared with mature large-cap pharma ranges, suggests investors are capitalizing future operating leverage rather than current cash generation. The forward EV/EBITDA of 29.79 implies only modest expected EBITDA improvement, which warrants monitoring given that the market is paying for growth the operating line has not yet demonstrated consistently.

Gross Margin Erosion Versus Operating Recovery

According to reported income statements, gross margin slid from 73.0% in 2024Q2 to 58.9% in 2026Q3, while operating margin swung from -43.7% to 13.0%, so the operating improvement appears to come from cost control rather than pricing or unit economics.

The gross margin decline may reflect rising per-patient manufacturing and logistics costs as volumes scale, a pattern consistent with individualized autologous production. Operating margin turning positive at 13.0% in the latest quarter is a meaningful inflection, yet it sits against a net margin of 14.4% that is not reconciled with negative operating cash flow. Investors should treat the operating recovery as early evidence that requires confirmation over several more quarters.

Returns Turning Positive From Deep Losses

Based on reported ratios, ROIC moved from -5.3% in 2024Q4 to 3.9% in 2026Q3 and ROE to 4.1%, a reversal that is directionally encouraging but still low relative to a roughly 1.3 billion dollar equity base.

The shift from negative to positive returns appears driven primarily by margin improvement rather than asset efficiency, since asset turnover of 0.21 remains very low for a commercial biotech. Returns of roughly 4% sit well below the cost of capital typically applied to this risk profile, suggesting the business has not yet created economic value on the capital deployed. Sustained ROIC above the cost of capital would be the clearer signal of compounding.

Deleveraging Shrinks Refinancing Exposure

As reported in financial statements, total debt fell from 389.3 million dollars in 2026Q1 to 167.4 million dollars in 2026Q3, lowering debt-to-equity from 0.40 to 0.13 and easing refinancing pressure considerably.

Interest coverage of 13.67 in the latest quarter, after a distorted 288.50 in the prior quarter, indicates that debt service is comfortable on current earnings, though the coverage series is too volatile to rely on heavily. The debt reduction appears to have been funded in part from cash accumulation, which suggests management prioritized balance sheet flexibility. Investors should monitor whether debt repayment continues without drawing down the cash reserve needed for operating burn.

Cash Cushion Covers Burn Under Stress

Based on reported figures, the current ratio of 3.95 and quick ratio of 3.82 in 2026Q3, backed by 460.7 million dollars of cash, provide a substantial buffer against near-term operating shocks, though the cushion has narrowed from 5.20 in 2025Q1.

Because the quick ratio is nearly identical to the current ratio, inventory dependence is low, which reduces the risk of a liquidity squeeze from unsold product. The declining current ratio trend suggests the liquidity buffer is being consumed gradually as operations are funded. Under a severe stress scenario, the reported cash balance covers many quarters of current negative operating cash flow, but that runway shortens quickly if working capital swings reverse.

Net Margin Overstates Cash Earning Power

According to reported quarterly figures, LEGN's 14.4% net margin in 2026Q3 coexists with an FCF margin of -11.5%, a gap that may make headline profitability a misleading gauge of the business's true earning power.

The most commonly misapplied ratio for a company like this is net margin, because collaboration accounting with Janssen and non-operating items can produce net income well above underlying cash generation. Free cash flow margin and operating cash flow relative to revenue are better anchors, since they capture the working capital and manufacturing cash demands that the income statement can defer. Investors should monitor whether net margin and FCF margin converge over the next several reporting periods.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open LEGN Terminal

LEGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LEGN — Frequently Asked Questions

Quick answers to the most common questions about buying LEGN stock.

What is Legend Biotech Corporation's P/E ratio?

Legend Biotech Corporation's current P/E ratio is -9999.0x. This places it at the 50th percentile of its historical range.

What is Legend Biotech Corporation's EV/EBITDA?

Legend Biotech Corporation's current EV/EBITDA is 29.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.

What is Legend Biotech Corporation's ROE?

Legend Biotech Corporation's return on equity (ROE) is -29.1%. The historical average is -34.6%.

Is LEGN stock overvalued?

Based on historical data, Legend Biotech Corporation is trading at a P/E of -9999.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Legend Biotech Corporation's profit margins?

Legend Biotech Corporation has 60.3% gross margin and -13.3% operating margin.